International Murex launching HIV RT drug resistance test in Europe by end of January.
This article was originally published in The Gray Sheet
Executive Summary
INTERNATIONAL MUREX LAUNCHING HIV RT DRUG RESISTANCE ASSAY IN EUROPE "at the end of this month," acting President and CEO Robert Cusick said Jan. 21 at a meeting with the New York Society of Security Analysts. The test is intended to detect HIV strains resistant to reverse transcriptase inhibitor therapies. Murex plans to introduce the test in the U.S. later this year for investigational use only.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.